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1 ARTICLE 
Abstract. Associated with the use of Zyderm Collagen 
Implant (ZCI) for soft tissue augmentation, the rate of 
localized hypersensitivity reactions to the initial test in- 
jection of ZCI range from 3.0-3.5% in the literature, and 
subsequent reactions to treatment have reportedly 
ranged from 1.1-5.0%. The inflammatory symptoms to 
the Collagen Test Implant occur within 72 hours in 2% 
of those injected, indicating a preexisting sensitivity to 
bovine collagen in this healthy population. Most adverse 
treatment reactions follow the first treatment and after 
injection of <5 ml of collagen. Furthermore, antibodies 
against collagen in sera of subjects reporting localized 
symptoms of hypersensitivity at test or treatment sites 
are specific for bovine interstitial collagens and show no 
cross-reactivity with human collagens. Thus, immuno- 
logic reaction to ZCI results in antibovine collagen anti- 
bodies and localized inflammatory symptoms in those 
few subjects who experience hypersensitivity to test or 
treatment. 
Glutaraldehyde cross-linked Zyplast Implant (ZI), has 
demonstrated a lower incidence of hypersensitivity re- 
actions than ZCI. In examining patients tested with ZI o r  
treated for intradermal and subdermal indications, we 
have experienced only 7 hypersensitivity reactions a t  test 
sites of Z1, out of 803 tested subjects, and only 3 reactions 
among 498 treated patients. Therefore, ZI appears to in- 
duce a lower incidence of hypersensitivity reactions than  
ZCI in man. 
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INTRODUCTION 
The extensive utilization of collagen-based bioma- 
terials for hemostatic devices, sutures, heart valve 
replacements, and vascular substitutes is based on 
its strong biocompatibility and weak immunogenic- 
ity.'-3 In the search for an injectable material for 
augmentation of soft tissue contour defects due to 
scars, rhytids, and genetic deformities, Knapp et 
al.4 demonstrated the successful use of type I col- 
lagen-the major natural structural component of 
the dermis-in such clinical indications. Purified, 
injectable bovine collagen (ZCI) has proved to be a 
valuable biomaterial for these  indication^."^ Clini- 
cal use of injectable collagen has demonstrated a 
low incidence of hypersensitivity reactions to this 
bovine collagen.8 
Glutaraldehyde cross-linked collagen has been 
associated with further reductions in immunoge- 
nicity as evidenced by enhanced biocompatibility of 
xenogeneic implants.y~10 We have begun to examine 
injectable cross-linked bovine collagen for soft tis- 
sue augmentation in man. These immunologic ex- 
periences are summarized here. 
MATERIALS AND METHODS 
Injectable ColIa~ciz 
Zyderm Collagen Implant (ZCI) was prepared from 
bovine hide as previously described"' and was uti- 
lized as a sterile, fibrillar suspension in phosphate- 
buffered saline at pH 7.2 at 35 or 65mgiml. ZI was 
also prepared from purified bovine collagen as de- 
scribed in detail by McPherson et al." and used as 
a 35mg/ml suspension in phosphate-buffered saline 
at pH 7.2. 
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ZCI Cliriicnl Llsc 
Data on patients tested intradermallv with 0.1 ml 
ZCI in the volar forearm and t r ea t e i  with ZCI for 
soft tissue contour defects were gathered from the 
multicenter clinical studies performed,' including 
9,427 tested subjects and 5,109 treated patients. Ad- 
ditional data have been gathered on patients 
treated with ZCI during four years (7181-6185) of 
postmarketing. During this time approximately 
200,000 patients were treated with ZCI domesti- 
cally, a s  determined by the volume of ZCI sold in 
the United States. Definitions of adverse reactions 
have been detailed previously.8 
ZI Cliriirril Usc 
Data presented here on people tested or treated 
with ZI were gathered in controlled clinical trials 
conducted under  the Investigational Device Exenip- 
tion rules of the U.S. Food and Drug Administra- 
tion, and  with appropriate Institutional Review 
Board -approved in formed consent from par ti ci pa t - 
i n s  subjects. In the Sensitivity Study, human vol- 
unteers were injected intradermally with a 0.1-ml 
test dose of ZI in the volar forearm. The test site 
was observed for hypersensitivity and sera were 
obtained both before injection and a t  intervals de- 
tailed in the text. Additional patient data have been 
obtained from patients under  study for the subder- 
ma1 treatment of keratoses of the feet, intradermal 
treatment of soft tissue defects, and subdermal 
treatment of contour irregularities with ZI. Local- 
ized hypersensitivity reactions were defined as  
erythema, induration, and/or pruritus, as  well as  
antibodies against bovine collagen. 
The Assay 
(ELISA) was performed as  previously described.'' 
In addition to a conjugate of wide antibody class 
specificity, '' peroxidase-Libeled rabbit antihuman 
IgG, IgA, or IgM antibody conjugates were utilized 
to measure class-specific antibody activities. These 
techniques provide sensitive and specific mecha- 
nisms t o  examine anticollagen humoral immune 
responses . 
Enzyme- L i n ke d 1 ni in u n o so rbe n t 
RESULTS AND DISCUSSION 
Following the extensive use of ZCI for the clinical 
treatment of dermal contour defects, several pub- 
lications have appeared ' , I 4  If' that examine the rate 
of hypersensitivity to test and treatment (Table 1). 
The response to test ranges from 3.0% in a study 
of  9,427 subjects by Cooperman et  al.' and 3.1% in 
a s tudy of 7,000 subjects by Castrow and Krul1,l4 to 
3.5% in an investigation of 300 patients by Kamer 
and Churukian. '' Similarly, these have 
reported treated site adverse reaction rates of 
1.1-1.5'%, while another report'" has indicated a 
higher incidence (5.0%) i n  202 patients (Table 1). 
These differences may be related to the number of 
patients examined, the specific demographics of the 
s tudy populations, or the clinical interpretation of 
symptoms of hypersensitivity. 
In a s tudy o f  reactions to skin test implantation 
of ZCI,s the time of onset of the symptoms provides 
a useful insight into the presence of sensitivity to 
bovine collagen in the healthy population. In Figure 
1, it can be seen that 70% of the hypersensitivity 
responses to test implantation (first exposure) with 
ZCI occur within 72 hours, and the data suggest a 
preexisting immunity to bovine collagen in these 
subjects. Of the remaining test site reactions, ap- 
proximately 1Ock take place from 3-7 days, and the 
Aiit ih0d.y Assn!/s 
Radioimmunoassay (RIA) for antibodies against 
collagen has been described in detail previously.12 
TABLE 1 
Localizecl Hypersensitivity Reactions to Zyderm Collagen Itnplant 
Rcfcreiicc 
Cooperman (1985)' 








Test I n l < ~ t i o n  
Treatment  
Tcs t I ii jc'c ti o n  
'r rea t m en t 
~~ ~ 
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remainder develop over approximately 1 month. It 
is of interest to note the presensitization, presum- 
ably through dietary exposure to collagen, of ap- 
proximately 2% of the prospective patient pool, 
which represents a healthy population; in addition, 
antibodies to bovine collagen have been demon- 
strated in the sera of 1 4 %  of uninjected, healthy 
 control^."^'^ The data suggest that those subjects 
who are a high responder genotype produce anti- 
bodies rapidly in vivo to a minimal antigenic ex- 
posure, such as through environmental exposure or 
the Collagen Test Implant, and as these subjects are 
detected after early exposures, late sensitizations 
are infrequently encountered.',I8 
Of the patients who are treated with ZCI, hy- 
persensitivity reactions can occur.R,14-1h In a multi- 
center clinical study of 5,109 treated patients,' it 
was found that increasing total volumes of ZCI uti- 
lized to treat these patients was not found to result 
in an  increasing incidence of hypersensitivity (Ta- 
ble 2). Hypersensitivity reactions were observed in 
1.6% of patients treated with < 5 ml, and exposure 
to larger volumes did not increase the incidence of 
sensitization to the implant material (Table 2). 
These results can be better understood in view of 
the incidence of hypersensitivity reactions follow- 
ing treatment relative to the number of treatment 
sessions (Fig. 2). In examining over 852 treatment 
site reactions in the estimated 200,000 patients 
treated with ZCI in the United States from July 1981 
to June 1985, most hypersensitivity (56%) followed 
the first treatment with ZCI, and 28% followed the 
second treatment. These data indicate that most hy- 
persensitivity reactions to bovine collagen take 
place after the earliest exposures (test and first 
treatment), and subsequent treatments with ZCI 
U i  
Days Days Weeks Weeks Keeks \Yceks 
Onset of 1nflariirnatoi.y S y m p  toriis 
* I t r sponses  (r i=20. i )  r r p o r t e d  t o  Collagen Corpora t ion  
du r i r ig  control led cliriical trials with 9427 pat ients .  
FIGURE 1. During a prospective study of 9,427 patients 
who received an intradermal test injection of ZCI, 284 
subjects experienced adverse reactions and the onset of 
inflammatory symptoms at test sites. The onset times of 
these reactions were monitored, and the results are ex- 
pressed as the percentage of the total reactions (n = 284) 
reported with increasing time following injection. 
have significantly diminished potential for eliciting 
a hypersensitivity response in situ (Fig. 2). To- 
gether, these findings (Figs. 1 and 2, Table 2) dem- 
onstrate that, in those subjects who display hyper- 
sensitivity to bovine collagen, sensitization to ZCI 
usually takes place after initial exposures to mini- 
TABLE 2 
Adverse Reactions Against Zyderm Collagen Implant 
According to Volumes Injecteda 
Totalb Number Number of 
Treatment of Patients Patients with Incidence of 
Volume Treated Adverse Reactions Adverse Reactions 
< 5 ml 3,885 
5-9.9 ml 845 
10-29 ml 355 
30-49 ml 19 
50-100 ml 4 



















"Data were collected by the Collagen Corporation during controlled clinical trials with 5,109 treated 
subjects.x 
bTotal amount of ZCI injected per patient during the entire course of treatment. 
'This group of patients includes subjects (n = 27) who were treated following an unreported positive 
test reaction. 
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Antibodies Against Zyderm Collagen Implant 
Immunoglobulin Class 
Trea tment  Site Reactions To ZYDER@ Collagen 
Relative t o  Number of Treatments  31 









1 2 3 4 5 6 
Number of Treatments 
Responses (n=652)  reported to Collagen Corporation from 7/81 to 6 /65 ;  
an  estimated 200.000 patients treated in the US. 
FIGURE 2. From 7/81 to 6/85, 852 patients reportedly ex- 
perienced hypersensitivity reactions to ZCI out of a pop- 
ulation of approximately 200,000 treated patients. The 
data are expressed as the percentage of the total reactions 
(n = 852) occurring after the last reported treatment 
session. 
ma1 volumes of material; repeated treatment with 
significant volumes of ZCI does not increase the 
incidence of hypersensitivity. 
It has been reported that hypersensitivity to ZCI 
can be monitored accurately by examining circulat- 
ing antibodies to bovine ~ o l l a g e n . ' ~ ~ ' ~ ~ ' ~ - ' *  As dem- 
onstrated in Table 3, localized hypersensitivity re- 
actions at sites of treatment with ZCI are associated 
with the detection of circulating antibodies against 
ZCI as measured by the ELISA or RIA, while sys- 
temic reports (such as malaise, arthralgia, and 
swelling) without localized symptoms have not 
been found to be associated with detectable anti- 
bodies against bovine collagen. However, no sig- 
i i  
: *  
I -,- .': . ;Ir -.I- :\ .,: 
FIGURE 3. Sera from patients experiencing adverse reac- 
tions at test sites (Tet Resp.) or treatment sites (Adv. 
Resp. Pt.), a s  well as untreated controls (Untrt. Control), 
were examined in the ELISA for IgG, A, and M antibodies 
against ZCI. All sera were assayed in duplicate at a 1:20 
dilution. Data are expressed as the absorbance values for 
all sera tested; for each group, the mean absorbance 2 SD 
is indicated by solid bars. 
nificant reactivity is observed against human inter- 
stitial  collagen^,'^,'^ and only infrequent, weak 
cross-reaction is observed against guinea pig or rat 
type I c01lagen.l~ As previously d e ~ c r i b e d , ' ~  anti- 
collagen antibodies are predominantly IgG and are 
found to the same extent in sera of patients reacting 
against a test or treatment with ZCI (Fig. 3 ) .  In ad- 
dition, while IgG is the predominant antibody class 
observed, sera from some adverse response pa- 
tients demonstrate circulating IgA anticollagen an- 
tibodies (Fig. 3 )  when compared to control sera 
from unexposed subjects; IgM antibodies against 
ZCI are not present. The presence of antibodies to 
bovine collagen has also been demonstrated in sera 
TABLE 3 
Development of Antibodies Against Zyderm Collagen Implant in Sera of 
Patients Experiencing a Localized Treatment Site Response but not with 
Systemic Complaints 
Anti-ZCI Antibodies" 
Number of Patients Positive Equivocal Negative 
Reaction Site Examined + + I -  - 
Treatment Site 93 82b 4 7h 
Systemic Only 25 Ob 3 22b  
__ 
(88.2%) (4.3%) (7.5%) 
(0%) ( 12.0% ) (88.0% ) 
'Sera examined by RIA or ELISA 
bChi-squared: p < U.UO1 
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of patients without symptoms of hypersensitivity 
after treatment with ZCI but in this case they do 
not appear to have any clinical significance. l7 Thus, 
hypersensitivity to ZCI, as measured through cir- 
culating anticollagen antibodies, is associated with 
IgG antibodies that react with sequential and con- 
formational determinants on bovine interstitial col- 
lagens and that demonstrate a species specificity for 
bovine collagen. 
Results from studies with glutaraldehyde-treated 
xenografts and allografts have indicated a minimal 
host response and prolonged graft s u r ~ i v a l . ~ ~ ' ~ ~ ' ~ - ~ ~  
These data in animals and human subjects have 
demonstrated the potential value of cross-linked 
dermal  graft^.^^'^,'^ In initial studies with cross- 
linked ZI in which 246 volunteers received skin 
tests, no circulating antibodies to bovine collagen 
were detected at 1 or 2 months after injection as 
compared to pretreatment control sera (Table 4). 
Even when subjects were examined at approxi- 
mately 6 or 12 months following exposure to the 
test dose, no follow-up serum was found to possess 
anticollagen antibody activity when compared to 
matched pretreatment control serum from the same 
subject (Table 4). Pretreatment and follow-up sera 
from only one subject displayed significant binding 
to ZCI. The absence of elevated levels of anticolla- 
gen antibodies in the sera of these subjects during 
the follow-up period suggests a lower level of reac- 
tivity than the 3% of subjects who react to a skin 
test of ZCI (Table 1). 
In ongoing clinical investigations with ZI for the 
intradermal and subdermal treatment of soft tissue 
defects, the results suggest that the expected inci- 
dence of hypersensitivity to both test and treatment 
DELUSTRO ET AL. 
Z Y P L A S P  Implant :  Inc idence  of Adverse 
React ions to  Test  o r  T r e a t m e n t  











Number of Patients 
no3 
4119 
FIGURE 4. Patients received test or treatment injections 
of Zyplast Implant as described in the text. The total 
number of patients injected at test or treatment sites is 
indicated at the last time they were clinically examined 
to date. Onset of adverse responses is demonstrated by 
the number of patients having test or treatment site re- 
actions and the time they were first reported. The data 
are expressed in months following the test injection or 
following the last treatment implantation for each pa- 
tient. Numbers above each bar represent the exact num- 
ber of patients per group. 
is significantly lower than that observed with ZCI. 
In these studies and the sensitivity study previ- 
ously discussed, we have tested 803 subjects with 
ZI and followed up 498 patients for >6 months (Fig. 
4). The finding of only 7 patients with adverse test 
site reactions of inflammation and immunity 
TABLE 4 
Summary of Immunologic Results in Zyplast Implant Sensitivity Studies 
in Human Volunteers 
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0.151 5 0.072 
0.151 2 0.077 
0.092 t 0.061 
0.085 ? 0.056 
0.254 -C 0.113 
0.245 k 0.123 
0.057 ? 0.039 
0.056 k 0.042 
0.143 2 0.055 
0.145 5 0.054 
"Groups 1-111 represent separately-enrolled study groups at different times. 
bData are expressed a s  the mean absorbance ? SD for 1:20 dilutions of sera 
Tretreatment serum from one subject was not available. 
dPretreatment sera from five subjects were not available. 
Zyderm Collagen 
0.096 ? 0.058 
0.091 2 0.060 
0.078 ? 0.051 
0,083 2 0.051 
0.138 t 0.075 
0.145 ? 0.097 
0.020 2 0.016 
0.021 ? 0.020 
0.081 k 0.089 
0.085 t 0.078 
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against collagen indicates a reaction rate of 0.9% 
(74303) to injection with a test dose of ZI, as com- 
pared to the 3-3.5% observed with ZCI (Table 1). 
As seen in Figure 4, 489 subjects have been treated 
with ZI, and 210 have been examined at >6 months 
following exposure. Only 3 adverse treatment re- 
actions with immunity against collagen have been 
observed, for an incidence to date of 0.6% (3/489), 
and two of these have occurred at >6 months fol- 
lowing treatment (2/210, 1.0%). The current data 
suggest that the immunogenicity of ZI is reduced 
below that found with ZCI (Table 1). 
CONCLUSION 
For many decades, millions of patients have bene- 
fited from treatment with collagen-derived sutures, 
hemostatic agents, vascular prostheses, and inject- 
able fibrillar collagen. The presence of naturally oc- 
curring antibodies to collagen has been reported in 
healthy human control p o p ~ l a t i o n s ' ~ , ~ ~ - ~ ~  but col- 
lagen-derived biomaterials have nonetheless 
proved to be of great clinical value and of minimal 
immunogenicity. 1-3 Injectable bovine collagen has 
provided a valuable clinical alternative for the treat- 
ment of dermal contour defects with few adverse 
events. 4-7 
When these adverse reactions do occur at test or 
treatment sites, they can be characterized histolog- 
ically as localized hypersensitivity reactions that 
demonstrate the local accumulation of a lympho- 
histiocytic infiltrate.26 This picture of an immune 
reaction is accompanied by the detection of circu- 
lating antibodies against bovine collagen in 
90-100% of these patients. 12,13,17,18 Antibody activ- 
ity against ZCI is associated clinically with local hy- 
persensitivity reactions, not with systemic com- 
plaints (Table 3). These antibodies have been well 
characterized, and while reacting with native or 
dehatured bovine interstitial collagen, they do not 
cross-react with human ~ o l l a g e n . ' ~ ~ ' ~ , ' ~  Le vels of 
circulating antibodies are similar in patients with 
hypersensitivity reactions following test or treat- 
ment with ZCI. Immunoblotting techniques have 
demonstrated binding of these antibodies to mul- 
tiple antigenic determinants in ZCI.I7 Extensive 
mapping for reactivity with cyanogen bromide pep- 
tides of al(1) and a2(I) chains of bovine type I col- 
lagen has verified this heterogeneity and identified 
al-CB6 and a2-CB4 as major antigenic determi- 
nants on the denatured m o l e c ~ l e . ' ~  This anti-ZCI 
reaction is best characterized as an immune re- 
sponse against bovine collagen that does not cross- 
react with collagens of other unrelated  specie^.^,'^,'^ 
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While little direct immunologic data are available 
on the immunogenicity of cross-linked collagen, the 
absence of significant clinical or histologic signs of 
a local hypersensitivity r e s p ~ n s e ~ ~ ' ~ ~ " - ~ ~  suggests 
that there is minimal recognition by the host. Clin- 
ical experience with ZI indicates that this assump- 
tion is correct.22 Elson22 has described hypersensi- 
tivity reactions at sites of ZCI only in patients 
treated with both ZCI and ZI; in these patients, the 
ZI-injected sites did not react. In this description of 
clinical experience in over 180 patients treated with 
ZI, none of the 62 patients treated with ZI alone 
experienced hypersensitivity reactions. Data from 
numerous studies in clinical trials and postmarket- 
ing use have shown that the incidence of hypersen- 
sitivity to ZI compares favorably to ZCI. These re- 
sults provide further evidence that glutaraldehyde 
cross-linked (Zyplast) collagen possesses less 
immunogenicity than its untreated counterpart 
(ZCI). The potential utility of Zyplast Implant in 
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